目的：非小细胞肺癌(non-small cell lung cancer，NSCLC)脑转移是影响NSCLC患者生存期及生存质量的重要因素，本研究将探讨克唑替尼在间变性淋巴瘤激酶(anaplastic lymphoma kinase，ALK)阳性NSCLC脑转移患者中的疗效。方法：筛选20例ALK阳性NSCLC脑转移患者，给予克唑替尼治疗，观察临床疗效。结果：克唑替尼治疗前基线有脑转移患者，颅内疗效部分缓解(partial response，PR)12例，疾病稳定(stable disease，SD)7例，疾病进展(progressive disease，PD)1例。客观缓解率(objective response rate，ORR)为60%，疾病控制率(disease control rate，DCR)为95%。中位无进展生存期(progression free survival，PFS)为6个月(95%CI：3.92~8.08)。结论：克唑替尼治疗ALK阳性NSCLC脑转移患者有效。
Efficacy analysis of crizotinib for brain metastases in ALK positive non-small cell lung cancer
Objective: Brain metastases have been recognized as an emerging complication in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). This study will explore the efficacy of crizotinib in ALK-positive NSCLC with brain metastases. Methods: Selected 20 cases of brain metastatic ALK positive NSCLC patients, received crizotinib therapy to clinical observation. Results: Among patients with brain metastases before treatment, 12 had partial response (PR), 7 stable disease (SD) and 1 disease progression (PD). Objective response rate (ORR) was 60%, and disease control rate (DCR) was 95%. Median progression free survival (PFS) was 6 months (95% CI: 3.92~8.08). Conclusion: Crizotinib is effective for brain metastases in ALK positive NSCLC.